Latest filing published 08 Sept 2026 for Opus Genetics, Inc., €775k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +73.1%Entry US$2.12 · Close 30 Oct 2026 US$3.67
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Cam Gallagher: trading record in brief
Cam Gallagher is a declared insider at 2 companies (chief executive); the most frequent names are Zentalis Pharmaceuticals, Inc. and Opus Genetics, Inc. We count 157 filings; the first trade dates from 7 April 2020 and the latest from 8 September 2026.
The open-market side counts 3 purchases for €275k alongside 135 sales for €19.5M. The totals exclude 5 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 18 share grants and 1 option exercise.
The record was last updated on 8 September 2026 with an option exercise (€775k) in Opus Genetics, Inc. The last purchase on record was published on 31 December 2025, which is 312 days ago. Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Cam Gallagher
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 784,314 shares@ US$1.150.30% mcap40.6% of flowCommon StockSEC:0001140361-26-035913:0
- 24,367 shares0Common StockSEC:0000905148-26-001785:0
- 67,000 shares0Common StockSEC:0000905148-26-000088:0
- 33,000 shares0Common StockSEC:0000905148-25-004511:2
- 83,000 shares@ US$1.977.3% of flowCommon StockSEC:0000905148-25-004511:1Canonical exit: 29 Mar 2026 (T+90)
- 81,000 shares@ US$1.97877.7% of flowCommon StockSEC:0000905148-25-004511:0Canonical exit: 29 Mar 2026 (T+90)
- 869,565 shares@ US$1.1548.6% of flowCommon StockSEC:0000905148-25-003152:0
- 79,504 shares0Common StockSEC:0000905148-25-001427:0
- 784,314 sharesCommon StockSEC:0000905148-25-001006:0
- 41,143 shares0Common StockSEC:0000905148-24-001711:0
- 9,597 shares@ US$11.981.7% of flowCommon StockSEC:0001725160-24-000127:0
- 1,173 shares@ US$11.440.2% of flowCommon StockSEC:0001725160-24-000041:0
- 11,552 shares@ US$11.541.1% of flowCommon StockSEC:0001725160-24-000030:1
- 192,500 shares0Common StockSEC:0001725160-24-000030:0
- 10,976 shares0Common StockSEC:0001140361-23-029020:0
- 18,526 shares@ US$26.214.1% of flowCommon StockSEC:0001725160-23-000125:1
- 9,242 shares@ US$26.39893.6% of flowCommon StockSEC:0001725160-23-000125:0
- 8,501 shares@ US$19.961.4% of flowCommon StockSEC:0001725160-23-000033:1
- 3,332 shares@ US$20.42441.0% of flowCommon StockSEC:0001725160-23-000033:0
- 572 shares@ US$23.040.1% of flowCommon StockSEC:0001725160-23-000022:1
- 9,428 shares@ US$22.22133.1% of flowCommon StockSEC:0001725160-23-000022:0
- 161,092 shares0Common StockSEC:0001725160-23-000019:0
- 500 shares@ US$24.870.1% of flowCommon StockSEC:0001725160-23-000008:1
- 9,500 shares@ US$24.11383.3% of flowCommon StockSEC:0001725160-23-000008:0
- 1,574 shares100.0% of flowCommon StockSEC:0001140361-23-000746:0
25 of 157 declarations
